Skip navigation

Strategies to Effectively Scale the Business and Best Practices for Accounting and Reporting

September 27-28, 2017
  • New Brunswick, NJ

CBI’s Finance & Accounting for Bioscience Companies is tailored to the distinctive business needs and technical accounting challenges for small-to-middle market bio/pharma companies. During this CPE accredited event, Finance and Accounting executives gain pre-revenue commercialization strategies, frameworks for managing gross-to-net estimates and mitigating risk, models to scale and grow a best-in-class finance function, timely updates on tax and legal matters and industry expertise for communications and investor relations.

Exceptional Content and Coverage on
High-Impact Issues, Including:

  • Healthcare industry regulations, changing policy and pricing pressures
  • Emerging global risks and international market considerations
  • Corporate tax reform and implications to life sciences industry
  • Talent retention and sourcing/building the finance team
  • Investor relations and communicating to the external market
  • Establishing financial systems, processes and controls
  • The new revenue recognition standard and impact on
    financial reporting, processes and disclosures
  • Industry roadmaps for commercializing new products
  • Considerations for IPOs, SOX controls and scaling the business
  • Implementing financial systems and ERP lessons learned

Previous Attendee Acclaim:

Great opportunity to hear first-hand
current issues within industry.

Controller, LifeCell Corporation

A great forum to meet people and have on point discussions about accounting and reporting topics facing our industry.

CFO, Triad Isotopes

This is an excellent conference and a great networking event.

Director, Technical Accounting & Reporting, Acorda Therapeutics, Inc.

September 27-28, 2017 | Hyatt Regency | New Brunswick, NJ

Finance & Accounting for Bioscience Companies

Strategies to Effectively Scale the Business and Best Practices for Accounting and Reporting

CBI’s Finance & Accounting for Bioscience Companies is tailored to the distinctive business needs and technical accounting challenges for small-to-middle market bio/pharma companies. During this CPE accredited event, Finance and Accounting executives gain pre-revenue commercialization strategies, frameworks for managing gross-to-net estimates and mitigating risk, models to scale and grow a best-in-class finance function, timely updates on tax and legal matters and industry expertise for communications and investor relations.

Exceptional Content and Coverage on
High-Impact Issues, Including:

  • Healthcare industry regulations, changing policy and pricing pressures
  • Emerging global risks and international market considerations
  • Corporate tax reform and implications to life sciences industry
  • Talent retention and sourcing/building the finance team
  • Investor relations and communicating to the external market
  • Establishing financial systems, processes and controls
  • The new revenue recognition standard and impact on
    financial reporting, processes and disclosures
  • Industry roadmaps for commercializing new products
  • Considerations for IPOs, SOX controls and scaling the business
  • Implementing financial systems and ERP lessons learned

Previous Attendee Acclaim:

Great opportunity to hear first-hand
current issues within industry.

Controller, LifeCell Corporation

A great forum to meet people and have on point discussions about accounting and reporting topics facing our industry.

CFO, Triad Isotopes

This is an excellent conference and a great networking event.

Director, Technical Accounting & Reporting, Acorda Therapeutics, Inc.

September 27-28, 2017 | Hyatt Regency | New Brunswick, NJ